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Evaluation of Macaca radiata as 
a non-human primate model of 
Dengue virus infection
Fumihiro Kato1,3, Yuki Ishida1, Akihiko Kawakami1, Tomohiko Takasaki2,4, Masayuki Saijo  2, 
Tomoyuki Miura1 & Takayuki Hishiki1,5
Dengue virus (DENV) causes a wide range of illnesses in humans, including dengue fever and dengue 
haemorrhagic fever. Current animal models of DENV infection are limited for understanding infectious 
diseases in humans. Bonnet monkeys (Macaca radiata), a type of Old World monkey, have been used 
to study experimental and natural infections by flaviviruses, but Old World monkeys have not yet 
been used as DENV infection models. In this study, the replication levels of several DENV strains were 
evaluated using peripheral blood mononuclear cells. Our findings indicated that DENV-4 09-48 strain, 
isolated from a traveller returning from India in 2009, was a highly replicative virus. Three bonnet 
monkeys were infected with 09-48 strain and antibody responses were assessed. DENV nonstructural 
protein 1 antigen was detected and high viraemia was observed. These results indicated that bonnet 
monkeys and 09-48 strain could be used as a reliable primate model for the study of DENV.
Dengue virus (DENV), which is transmitted to humans by Aedes mosquitoes, is the aetiological agent of dengue 
fever (DF) and dengue haemorrhagic fever (DHF), a self-limited febrile illness1. DF is relatively mild, but DHF 
leads to life-threatening dengue shock syndrome (DSS); the mortality rates of DHF and DSS in untreated cases 
exceed 20%, but decrease to less than 1% with proper medical care2. DENV infects 50–100 million humans annu-
ally in tropical and subtropical regions, posing a considerable threat to public health in over 100 countries3.
Despite great concern worldwide, current strategies for prevention and treatment are not sufficient, partly 
owing to a lack of animal models reflecting dengue clinical symptoms. Experimental animal models have been 
established for various viruses, such as retroviruses and influenza virus; these models are indispensable for evalu-
ating the antiviral activity and side effects of potential treatments and for antiviral drug development. Moreover, 
animal models can be used to determine the dynamics and pathological mechanisms of viruses, which can facil-
itate the development of appropriate antiviral strategies4–8.
Some mouse and non-human primate (NHP) models have been developed for the study of DENV9–11. 
However, these animal models have limits for pathological and virologic analyses and are genetically differen-
tiated from humans12. In an immunocompromised mouse model in which interferon-α, -β and -γ receptors 
were knocked out, highly pathogenic DENV infection was observed. However, an immunological response was 
not observed using immunocompromised mice and mouse models are not sufficient for studies of human dis-
ease13. The common marmoset has also been used as an animal model of DENV and high viraemia and immune 
responses corresponding to those in humans have been observed10,14. However, the common marmoset is a New 
World monkey and Old World monkeys may be more representative of humans. New world monkeys differ 
from Old World monkeys with respect to immune responses, including differences in major histocompatibility 
complex alleles and antibody cross reactivity. Indeed, Old World monkeys are more similar to humans than are 
other available animal models15–17. Old World monkeys have been used as DENV infection models18–21. However, 
experimental inoculation results in low viraemia levels and only mild symptoms22. Therefore, the establishment 
of new animal models that are genetically closely related to humans and have reproducible symptoms of human 
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DENV infection would provide a powerful tool for understanding the mechanisms of DENV-induced pathogen-
esis and for the development of antiviral drugs and vaccines.
Bonnet monkeys (M. radiata) are indigenous to Southern India, where DENV circulates widely. In previous 
studies, Kyasanur forest disease virus (KFDV), tick-borne encephalitis virus (TBEV), Japanese encephalitis virus 
(JEV) and West Nile virus (WNV) have been inoculated into bonnet monkeys, resulting in high viraemia23–25. 
Furthermore, neutralisation antibodies have been detected after natural infection in bonnet monkeys26. However, 
the experimental inoculation of DENV using bonnet monkeys has not yet been reported.
Some reports have shown that sylvatic DENV is transmitted between NHPs and mosquitoes in the sylvatic 
environment. It is phylogenetically distinct from urban DENV circulating in humans27–31. It is thought that syl-
vatic DENV is an effective candidate challenge virus for the development of an NHP model.
In this study, to develop a novel NHP model for DENV infection, we evaluated the replication efficiency of five 
DENV isolates using peripheral blood mononuclear cells (PBMCs) derived from M. radiata. The most replicative 
DENV, 09-48 strain, was used to infect bonnet monkeys and a biological analysis was performed using plasma 
samples. We also performed a phylogenetic analysis to determine the relationships between this highly replicative 
strain and other isolates.
Results
Comparison of the replication of clinically isolated DENVs in PBMCs of M. radiata. To investi-
gate whether clinically isolated DENV strains were capable of efficient replication in primary cells derived from 
M. radiata, equal MOIs of DENV strains were infected and titres of progeny viruses from PBMCs at 2 dpi were 
measured by plaque assays. The viral titres of DENV-1 (10-07), DENV-2 (09-74), DENV-3 (09-59), DENV-3 
(00-40) and DENV-4 (09-48) were 4.7 × 101, 4.9 × 102, 2.7 × 101, 8.3 × 101 and 1.5 × 104 PFU/mL, respectively 
(Fig. 1). DENV-4 (09-48) showed significantly higher progeny virus titres than those of other isolates, suggesting 
that DENV-4 (09-48) has potential applications as a challenge virus candidate. Furthermore, the sequence of the 
09-48 strain was determined (accession number: LC069810) and analysed using phylogenetic methods (Fig. 2). 
DENV-4 (09-48 strain) belonged to a cluster of strains isolated from Indonesia in 2004 and 2008 and was diver-
gent from sylvatic strains.
Infection of M. radiata with DENV-4. Three M. radiata were inoculated intravenously with 1 × 106 PFU 
of DENV-4 (09-48 strain). The collection of plasma samples, measurement of rectal temperatures and observa-
tions of the clinical presentation of monkeys were performed before inoculation and at 2, 3, 5, 7, 10, 14 and 29 dpi. 
Viraemia is a major clinical manifestation of DENV infection. The amount of viral RNA was analysed in plasma 
by quantitative RT-PCR at various time points. The viral load peaked at 2 dpi, reaching 2.2–4.0 × 106 copies/mL, 
followed by a gradual decrease to below the limit of detection and there were no significant differences among M. 
radiata individuals (Fig. 3a). Furthermore, the NS1 antigen, as examined by ELISA, was detected in all plasma 
samples derived from DENV-4-infected M. radiata (Fig. 3b). These results suggested that DENV-4 propagated in 
all M. radiata. However, no clinical symptoms, e.g. haemorrhage or weight loss, were observed and rectal temper-
atures were not substantially altered at any time point (Fig. 3c and d).
Profiles of leukocytes and platelets in blood. Collected blood samples were analysed to determine their 
cell properties using an automated haematology analyser. Both leukocytes and platelets were slightly decreased 
at 2, 3, 5 and 7 dpi (Fig. 3e and f).
Analysis of antibody responses. IgG and IgM antibodies against DENV antigens were assessed by ELISA. 
In cases of DENV infection, IgM antibodies can be detected immediately and IgG antibodies subsequently 
Figure 1. DENV replication in M. radiata PBMCs. PBMCs derived from M. radiata were infected with DENV 
at an MOI of 0.1. At 2 dpi, the viral titres in culture supernatants were determined by plaque assays using BHK-
21 cells and three independent tests were performed. Results were compared using the Student’s t-test against 
DENV-4 and P < 0.05 (*) was considered statistically significant.
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increase. We detected IgM antibodies after 3 or 5 dpi, with a peak at 11 dpi. We detected IgG antibodies at 11 or 
14 dpi and their levels increased thereafter (Fig. 4a and b). These results indicated that DENV-4 propagated and 
induced specific IgM and IgG antibodies in M. radiata.
Neutralisation antibodies. Neutralisation antibodies were measured by plaque reduction assays. 
Neutralisation antibodies were observed at 5 or 7 dpi. At 29 dpi, neutralisation antibody titres for all three mon-
keys were increased to over 1:160 (Table 1).
Figure 2. Phylogenetic analysis of DENV 09-48 strain. A phylogenetic tree was constructed using the 
maximum likelihood method with the DENV-4 polyprotein coding region. The DENV-4 09-48 strain is 
indicated by the black triangle. The country and year of isolation as well as the accession number are indicated.
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Discussion
In this study, five clinically isolated DENV strains were evaluated to determine viral replication in PBMCs derived 
from bonnet monkeys. DENV-4 09-48 strain was isolated from a traveller returning to Japan from India and 
showed the most efficient replication in PBMCs, suggesting that this strain may be a suitable challenge virus in 
Figure 3. Detection of viral RNA and NS1 protein antigen and profiles of leukocytes and platelets. (a) Plasma 
samples were collected on the indicated days. The amount of viral RNA in the plasma of three individual M. radiata 
was determined by qRT-PCR. The dotted line indicates the detection limit (<100 copies/mL). Growth curves 
of M. radiata were evaluated using two-way ANOVA. (b) The level of the DENV NS1 antigen was analyzed by 
ELISA. The dotted line indicates the criterion for positive or negative results. Index values of greater than 2 were 
considered positive. (c) Body weights of three M. radiata. (d) Rectal temperatures of three M. radiata. (e and f) 
Blood samples were collected on the indicated days. The absolute number of leukocytes (e) and platelets (f) in 
blood were determined using an automated haematology analyser. Results were compared using the paired t-test 
against pre-inoculation levels; P < 0.05 (*) and P < 0.01 (**) were considered statistically significant.
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bonnet monkeys. An evaluation of growth kinetics in PBMCs before in vivo analyses may provide insights into 
the appropriate growth level in vivo for this challenge virus.
Sylvatic DENV, which is distinguished from urban DENV circulating in humans, has been evaluated in var-
ious studies27–31. Sylvatic DENV cycles between NHPs and mosquitoes in the sylvatic environment and studies 
have evaluated its genome and isolation. If sylvatic DENV is acclimatised to monkeys, it may be an effective can-
didate challenge virus for the development of an NHP model. The sequence of the 09-48 strain indicated that it 
belongs to the urban DENV cluster and is divergent from the sylvatic DENV cluster. Some sequence differences 
may affect viral replication in PBMCs; further analyses are needed.
In this study, 09-48 strain was intravenously injected into M. radiata. The results should be interpreted with 
caution because intravenous inoculation is a different route compared with natural DENV infection. In cases 
of experimental infection in Old World monkeys, viraemia levels are typically very low. However, following the 
infection of M. radiata with DENV-4 09-48 strain, viraemia levels were very high19,32,33, even soon after infection. 
The peak viral titre was observed within 2 dpi. The NS1 antigen, which is a product of viral infection and rep-
lication, was also observed, as evidence of DENV replication in M. radiata in vivo and inoculated DENV stock 
reached a titre of 5.0 × 108 copies/mL. The monkeys used in this study weighed 6–7 kg and the total serum quan-
tity was approximately 250 mL. After inoculation, there was an estimated 2.0 × 106 copies/mL and viral titres at 
2 dpi were similar to or greater than the inoculation titre, suggesting that much of the detected viral genome was 
derived from in vivo replication. Additionally, M. radiata showed lower viraemia levels than those of marmosets, 
but higher viraemia levels than those of many other Old World monkeys.
In typical DENV infection in humans, IgM antibodies are detected 3–5 days after onset and IgG antibodies are 
detected 10–14 days after onset34,35. Human-like antibody responses against DENV infection are important for 
the establishment of animal infection models. However, in humans or marmosets, infection with DENV resulted 
in higher IgG or IgM antibody responses compared with those in M. radiata. Notably, M. radiata could be applied 
for antiviral drug or antibody medical treatment for DENV infection owing to the similarities in genetic back-
grounds between M. radiata and humans.
The platelet and leukocyte counts were slightly and transiently decreased by about 24% and 54%, respectively, 
similar to the counts in previous marmoset experiments14. Furthermore, the recovery times of leukocytes and 
platelets were similar to those of humans following DENV infection36. In this study, the body weight and the 
amount of blood collected for M. radiata were similar to those for other experiments using Old World mon-
keys6,37, suggesting that blood collection did not affect the hemogram properties caused by DENV-4 infection.
Figure 4. Analysis of DENV-specific IgM and IgG antibodies. Plasma samples were collected on the indicated 
days. The levels of DENV-specific IgM (a) and IgG (b) antibodies were detected by ELISA. MR01 is indicated as 
circles/solid line, MR02 is indicated as squares/broad-dashed line and MR03 is indicated as triangles/narrow-
dashed line in all figures. The dotted line indicates the criterion for positive or negative results. Index values of 
greater than 2 were considered positive.
Days postinoculation 2 3 5 7 9 11 14 29
MR01 <1:10 <1:10 <1:10 1:40 1:40 1:160 1:160 1:160
MR02 <1:10 <1:10 <1:10 1:40 1:40 1:40 1:160 1:160
MR03 <1:10 <1:10 1:10 1:40 1:40 1:160 1:80 1:160
Table 1. Neutralising antibody titres targeting DENV-4.
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Neutralisation antibodies were also detected by plaque reduction assays in this study. In comparison with 
DENV infection results in primate models, such as marmosets and rhesus macaques, neutralisation titres in 
DENV-4-infected M. radiata were similar19,38. Compared with human infection, neutralisation antibody levels 
were significantly lower; however, the timing of the increases in IgM, IgG and neutralisation antibodies was sim-
ilar, suggesting that this model was useful for the evaluation of neutralisation levels induced by vaccines or viral 
infection.
A previous report has shown that clinical symptoms, such as rash, were induced by DENV infection in 
NHPs19. In this study, although clear clinical symptoms were not observed, a rash-like bruise was present in 
MR02 (data not shown). However, this bruise was not analysed using pathological methods, such as immunos-
taining. Furthermore, viraemia and other responses in MR02 were not different from those in MR01 and MR03. 
Therefore, this bruise may not a result of DENV infection. In animal model inoculation studies, observations of 
human-like clinical symptoms are essential. However, in this study, these symptoms of DENV infection were not 
found and further analyses are needed to explain this result.
In conclusion, M. radiata showed high viraemia levels and human-like antibody responses after infection with 
DENV-4 09-48 strain. The establishment of new animal models, particularly Old World monkeys, is needed to 
understand the molecular mechanisms of DENV infection and to develop effective antiviral drugs and vaccines. 
Further studies of M. radiata and other Old World monkeys as DENV infection models are needed.
Methods
Cells and viruses. BHK-21 and C6/36 cells were maintained in Eagle’s Minimum Essential Medium con-
taining 10% foetal bovine serum (FBS) and Non-Essential Amino Acid. PBMCs were prepared from ethylen-
ediaminetetraacetic acid-treated whole blood in lymphocyte separation medium. PBMCs were resuspended in 
R-10 medium supplemented with 40 μg/mL gentamicin, 50 μM 2-mercaptoethanol and 25 μg/mL concanavalin 
A and cultured for 16–20 h at 37 °C. Before virus infection, the cells were cultured for an additional 2 days in 
R-10 medium containing 40 μg/mL gentamicin, 50 μM 2-mercaptoethanol and 100 IU/mL recombinant human 
interleukin-2. DENVs were propagated with C6/36 cells and the titres were measured by plaque forming unit 
(PFU) assays using BHK-21 cells. DENV-1 10-07 was isolated in 2010 from a traveller returning from Indonesia; 
DENV-2 09-74 was isolated in 2009 from a traveller returning from India; DENV-3 09-59 and 00-40 were isolated 
in 2009 from a traveller returning from Papua New Guinea and in 2000 from a traveller returning from Thailand, 
respectively; and DENV-4 09-48 was isolated in 2009 from a traveller returning from India39,40.
Analysis of viral replication in PBMC of M. radiata. Growth properties of five clinically isolated strains 
were investigated in PBMCs derived from three bonnet monkeys and 1 × 106 cells for each type of PBMC were 
seeded on 24-well plates and infected with DENV at a multiplicity of infection (MOI) of 0.1. At 2 days after 
infection, supernatants were harvested and viral titres were measured by plaque assays, as described previously41.
Infection of M. radiata with DENV-4. M. radiata was used in accordance with the institutional regulations 
approved by the Committee for Experimental Use of Nonhuman Primates of the Institutes for Virus Research, 
Kyoto University, Kyoto, Japan. Briefly, 1 × 106 PFU of DENV-4 09-48 strain was intravenously inoculated to three 
M. radiata (6–7 kg in body weight) after anaesthetisation with ketamine hydrochloride (Daiichi-Sankyo, Tokyo, 
Japan). Blood samples were collected and rectal temperatures were measured at 2, 3, 5, 7, 10, 14 and 29 days 
postinoculation (dpi). Collected blood samples were separated into serum and cells by centrifugation.
Profiles of leukocytes and platelets in blood. The numbers of leukocytes and platelets in blood were 
measured using a multiple automatic blood cell counting device (KX-21; Sysmex, Kobe, Japan).
IgG and IgM antibodies and nonstructural protein 1 (NS1) antigen detection. Detection of IgG 
and IgM antibodies and anti-NS1 antigen in the serum was performed using enzyme-linked immunosorbent 
assays (ELISAs) with Dengue Virus IgG DxSelect (Focus Diagnostics, Cypress, CA, USA), Dengue Virus IgM 
Capture DxSelect (Focus Diagnostics) and a PLATELIA DENGUE NS1 AG Kit (Bio-Rad, Hercules, CA, USA). 
Values of greater than 2 were considered positive according to the manufacturer’s protocol.
Plaque reduction assay. Sera were diluted with FBS by 10–160-fold and mixed with 50 PFU of virus at a 
ratio of 1:1. The mixed samples were then incubated at 37 °C for 30 min. BHK cells were seeded in 12-well plates 
(5 × 105 cells/well) and inoculated with samples for 1 h. After inoculation, E-MEM containing 2% FBS and 1% 
methyl cellulose was overlaid and incubated for 5–6 days. Fixation and staining were applied as described for 
plaque assays. Samples with 50% fewer plaques than those of the negative control were considered positive.
Real-time RT-PCR. Viral RNA was extracted from plasma using a High Pure Viral RNA Kit (Roche, 
Basel, Switzerland) according to the manufacturer’s instructions. A quantitative real-time RT-PCR anal-
ysis of the envelope region of the DENV-4 genome was performed using RNA-direct Real-time PCR 
Master Mix (Toyobo, Osaka, Japan) and a StepOnePlus System (Applied Biosystems, Foster City, CA, 
USA). DENV-4-specific primer-probe sets (D4Ten711s forward: GGTGACRTTYAARGTHCCTCAT, 
D4Ten786c reverse; WGARTGCATRGCTCCYTCCTG and TaqMan probe: D4Ten734p probe, 
CCAAGAGACAGGATGTGACAGTGCTRGGATC), developed by Ito et al.39, were used in this study. Note that 
in the primer sequences, W indicates a mix of A and T, R indicates A and G, Y indicates C and T and H indicates 
A, T and C. The real-time RT-PCR conditions were as follows: denaturation (90 °C for 30 s), reverse transcription 
(61 °C for 20 min), denaturation (95 °C for 1 min) and 40 cycles of amplification and quantification (95 °C for 15 s, 
57 °C for 1 min). The copy number was determined by the relative quantification method using the synthesized 
RNA template.
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Determination of DENV-4 09-48 strain sequences. DENV RNA was isolated using a High Pure 
viral RNA Kit (Roche) according to the manufacturer’s instructions. cDNA was synthesised from viral RNA 
and three fragments were amplified by polymerase chain reaction (PCR) using Q5 High-Fidelity 2× Master Mix 
(NEB, Ipswich, MA, USA) and the following primers (fragment1: D4.001 f, AGTTGTTAGTCTGTCTGGACCG; 
D4.4620r, TCCCAAACAACCCTCTTTGCAT; fragment2: D4.4210 f, TCCCTTTAGCTGGCCCAATGGT; 
D4.9427r, TGGCGGATGAGTTGTACTTCCAT; fragment3: D4.8976 f, CGAGCAATCTGGTATATGTGG; 
D4.10649r, AGAACCTGTTGGATCAACAACAC). Purified PCR products were sequenced using primers 
(Supplementary Table S1) and analysed using a Big Dye Terminator v3.1 Kit and an ABI 3500 sequencer (Applied 
Biosystems).
Phylogenetic analysis. A phylogenetic tree using the full sequence of the 09-48 strain was constructed by 
the maximum-likelihood method42.
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